Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
Raúl D. Santos, Andrea Ruzza, G. Kees Hovingh, Claudia Stefanutti, François Mach, Olivier Descamps, Jean Bergeron, Bei Wang, Andrea Bartuli, Paola Sabrina Buonuomo, Susanne Greber‐Platzer, Ilse K. Luirink, Ajay Bhatia, Frederick J. Raal, John J.P. Kastelein, Albert Wiegman, Daniel Gaudet
Topics & Concepts
MedicineEvolocumabPlaceboAdverse effectRandomized controlled trialClinical endpointInternal medicinePopulationCholesterolLipoproteinPathologyApolipoprotein A1Alternative medicineEnvironmental healthLipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismInflammatory Bowel Disease